Biogen, Partner Say Late-Stage Trial of Lupus Erythematosus Drug Candidate Met Primary Endpoint

MT Newswires Live11-19

Biogen (BIIB) and its collaboration partner UCB said Tuesday their phase 3 trial evaluating dapirolizumab pegol in patients with moderate-to-severe systemic lupus erythematosus met its primary endpoint.

Results of the late-stage trial showed "significant clinical improvement" in disease activity in the subject patients, as well as a generally favorable safety profile, the companies said.

However, the trial failed to achieve statistical significance in the first secondary endpoint, they said. The companies plan to start a second phase 3 trial of the drug candidate in 2024.

Systemic lupus erythematosus is a chronic autoimmune disease affecting multiple organ systems, mainly in women.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment